How do the mechanisms differ — GIP vs. glucagon?
To understand the survodutide vs tirzepatide comparison, you first have to understand what each molecule targets beyond GLP-1.
Tirzepatide (Mounjaro/Zepbound, Eli Lilly) is a dual GIP/GLP-1 receptor agonist. GIP stands for glucose-dependent insulinotropic polypeptide — an incretin hormone that potentiates insulin secretion in a glucose-dependent way. GIP receptors are expressed on pancreatic beta cells, adipocytes, and in the brain. Activating both GIP and GLP-1 receptors simultaneously appears to produce additive or even synergistic effects on appetite regulation, insulin sensitivity, and fat metabolism. Tirzepatide is FDA-approved and has robust Phase 3 trial data across multiple indications.
Survodutide(BI 456906, Boehringer Ingelheim) takes a different approach: it is a dual GLP-1/glucagon receptor agonist. Glucagon is typically thought of as the counterpart to insulin — it raises blood glucose and promotes hepatic glucose production. But glucagon also has thermogenic properties: it increases energy expenditure, promotes fat oxidation, and can suppress appetite. By co-activating both GLP-1 and glucagon receptors, survodutide aims to combine GLP-1’s satiety effects with glucagon’s fat-burning and energy-expenditure effects.
What the clinical evidence shows so far
Tirzepatide: robust Phase 3 data
Tirzepatide has a substantial clinical evidence base. The SURMOUNT program — a series of Phase 3 trials — demonstrated meaningful average reductions in body weight in adults with obesity. SURMOUNT-1 showed average weight reduction of up to approximately 20–22% from baseline at the highest dose over 72 weeks. The more recent SURMOUNT-5 trial compared tirzepatide head-to-head with semaglutide and demonstrated greater average weight reduction with tirzepatide in adults with obesity without type 2 diabetes.
These are population averages in controlled trial conditions, not guarantees for individual patients. Response varies. Clinician supervision, dose titration, and behavioral support all influence outcomes.
Survodutide: Phase 2 data, Phase 3 underway
Survodutide’s pivotal Phase 2 data, published in the New England Journal of Medicine in 2024, showed dose-dependent average weight reductions of up to approximately 19% from baseline at 46 weeks. These results generated significant attention because they placed survodutide in the same approximate range as tirzepatide in early-stage data — though Phase 2 and Phase 3 trials are not directly comparable in methodology or scale.
Survodutide is also in Phase 3 trials for MASH (metabolic dysfunction-associated steatohepatitis), a serious liver condition with no approved pharmacologic treatments at the time of writing. Positive data in MASH could be particularly significant, as GLP-1/glucagon dual agonism directly addresses pathways relevant to hepatic fat accumulation.
The Phase 3 obesity program will be the key determinant of survodutide’s regulatory fate. Phase 2 results, even impressive ones, do not predict Phase 3 success with certainty.
What do the side effect profiles look like?
Both drug classes share a GLP-1 foundation, which means they share several common side effects:
- Gastrointestinal effects — nausea, vomiting, diarrhea, and constipation are the most commonly reported. These are typically most prominent during dose escalation and often subside with time. Both tirzepatide and survodutide showed GI side effects in trials.
- Injection site reactions — both are administered by subcutaneous injection.
- Heart rate changes — GLP-1 receptor agonists can modestly increase resting heart rate; this has been observed with both molecules.
Survodutide’s glucagon component adds a theoretically distinct risk profile: elevated glucagon activity can increase glucose production, though the clinical relevance of this in the context of GLP-1 co-stimulation appears modest based on Phase 2 data. Longer-term Phase 3 data will be needed to fully characterize survodutide’s safety profile at scale.
The decisive difference is access, not mechanism: tirzepatide is prescribable today and survodutide is not.
Is survodutide available today, and how does FDA status differ from tirzepatide?
This is the most important practical difference for anyone asking whether they can access these medications today.
Tirzepatide is FDA-approved under branded products (Mounjaro for type 2 diabetes; Zepbound for weight management). Compounded tirzepatide has been available through licensed 503A pharmacies during periods of FDA-acknowledged shortage. The FDA shortage determination for tirzepatide has been a subject of regulatory evolution — patients should work with a licensed clinician who can advise on current availability and appropriate access pathways.
Survodutide is not FDA-approved as of mid-2026 and is not commercially available. It cannot be prescribed outside of a clinical trial setting. If you see anyone claiming to sell or prescribe survodutide through a telehealth platform or online pharmacy, that is a regulatory red flag.
Survodutide vs tirzepatide: head-to-head comparison
| Feature | Tirzepatide | Survodutide |
|---|---|---|
| Receptor targets | GIP + GLP-1 | GLP-1 + Glucagon |
| FDA status | Approved (Mounjaro / Zepbound) | Not approved (Phase 3) |
| Best weight-loss data | ~22% mean reduction at 15 mg (SURMOUNT-1, 72 wks) | ~19% mean reduction at highest dose (Phase 2, 46 wks) |
| Trial phase | Phase 3 complete; approved | Phase 3 underway (obesity + MASH) |
| Compounded 503A access (US) | Available (shortage periods; clinician Rx) | Not available |
| Route of administration | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection (trials) |
What does this mean for patients today?
If you are researching weight management options now, the relevant landscape includes GLP-1 receptor agonists and dual agonists that are currently approved and accessible through licensed clinicians. Compounded semaglutide and compounded tirzepatide — when prescribed by a licensed clinician and dispensed by a USA-based 503A pharmacy — are the current access pathway for most patients without commercial-product insurance coverage.
Survodutide represents the next wave of the pipeline. Its Phase 3 data, if positive, could meaningfully expand options in the coming years. The correct posture today is to follow the evidence as it develops — not to seek unapproved versions through unregulated channels.
If you’re interested in what is available now, a clinician consultation can help you understand which FDA-reviewed or appropriately compounded options best fit your health profile and goals. You can also learn more about compounded tirzepatide at PepScribe or read our semaglutide overview for more context on the existing GLP-1 class.
Frequently asked questions
What is the difference between survodutide and tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist with both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) activity. Survodutide is a dual GLP-1/glucagon receptor agonist — it targets the glucagon receptor instead of GIP. The difference in receptor targets leads to meaningfully different downstream pharmacology.
Is survodutide FDA-approved?
As of mid-2026, survodutide (BI 456906, developed by Boehringer Ingelheim) is not FDA-approved. It is in Phase 3 clinical development. Tirzepatide (Mounjaro/Zepbound) is FDA-approved for specific indications. Neither branded tirzepatide nor survodutide is available as compounded semaglutide or tirzepatide from licensed 503A pharmacies.
Can I get survodutide through a telehealth clinic?
No. Survodutide is not approved or commercially available. Only FDA-approved medications and Category 1 bulk substances can be legally prescribed or compounded in the USA. Clinicians cannot prescribe an unapproved investigational drug outside of a clinical trial.
How does tirzepatide compare to semaglutide for weight management?
Head-to-head trial data (the SURMOUNT-5 trial) suggests tirzepatide produced greater average weight reduction than semaglutide in adults with obesity without type 2 diabetes. Both are clinician-prescribed medications; neither represents a guaranteed outcome for any individual patient.
What does the glucagon receptor do that GIP does not?
Glucagon typically promotes hepatic glucose production and has thermogenic effects — it raises energy expenditure. Survodutide's glucagon receptor agonism is theorized to contribute to greater fat oxidation and potentially more pronounced weight reduction compared to GLP-1 alone. GIP (targeted by tirzepatide) enhances insulin secretion and may also directly affect adipose tissue metabolism, but via a different pathway.
When might survodutide become available?
Survodutide is currently in Phase 3 trials for obesity and MASH (metabolic dysfunction-associated steatohepatitis). Regulatory submission timelines depend on trial completion and FDA review — typically 1–3 years from Phase 3 readout to potential approval if trials succeed. No approved product date has been announced as of this writing.